RT Journal Article
SR Electronic
T1 Improved COVID-19 Serology Test Performance by Integrating Multiple Lateral Flow Assays using Machine Learning
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.15.20154773
DO 10.1101/2020.07.15.20154773
A1 Mowery, Cody T.
A1 Marson, Alexander
A1 Song, Yun S.
A1 Ye, Chun Jimmie
YR 2020
UL http://medrxiv.org/content/early/2020/07/16/2020.07.15.20154773.abstract
AB Mitigating transmission of SARS-CoV-2 has been complicated by the inaccessibility and, in some cases, inadequacy of testing options to detect present or past infection. Immunochromatographic lateral flow assays (LFAs) are a cheap and scalable modality for tracking viral transmission by testing for serological immunity, though systematic evaluations have revealed the low performance of some SARS-CoV-2 LFAs. Here, we re-analyzed existing data to present a proof-of-principle machine learning framework that may be used to inform the pairing of LFAs to achieve superior classification performance while enabling tunable False Positive Rates optimized for the estimated seroprevalence of the population being tested.Competing Interest StatementThe Marson Lab received gifts from Anthem Blue Cross Blue Shield and the Chan Zuckerberg Biohub for COVID-19 serology test assessment efforts.Funding StatementThe Marson Lab received gifts from Anthem Blue Cross Blue Shield and the Chan Zuckerberg Biohub for COVID-19 serology test assessment efforts.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All data collection and analyses were approved by UCSF and ZSFGH IRB.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available upon request.